Core Viewpoint - The company has decided to terminate the clinical research and development of the SY-009 project due to the assessment of its progress, investment risks, and future market value, aiming to allocate resources more effectively to its advantageous projects [1][2]. Group 1: Drug Information - Drug Name: SY-009 Capsule - Dosage Form: Capsule - Specifications: 0.5mg, 5mg - Registration Category: Class 1 Chemical Drug - Applicants: Yabao Pharmaceutical Group Co., Ltd., Suzhou Yabao Pharmaceutical Research Co., Ltd. - Approval Numbers: 2018L02807, 2018L02808, 2024LP02207 [1]. Group 2: R&D Status and Termination Reasons - SY-009 is a Sodium-glucose Cotransporter 1 (SGLT1) inhibitor aimed at reducing postprandial glucose absorption for treating type 2 diabetes. It received clinical trial approval in July 2018 and completed three Phase I and one Phase II clinical studies by March 2024 [1]. - The Phase II clinical study results indicated that while there was a dose-response relationship, the primary efficacy endpoint was not met. The uncertainty and significant investment required for further development led to the decision to terminate the project [1][2]. Group 3: R&D Investment - Total R&D investment for SY-009 amounted to 87.87 million yuan, with 32.08 million yuan expensed and 55.79 million yuan capitalized [2]. Group 4: Asset Impairment Provision - The company has fully recognized an asset impairment provision for the capitalized amount of SY-009, amounting to 55.79 million yuan, based on the project's termination and the absence of potential buyers for the related proprietary technology [3][5][6]. - This impairment provision will reduce the company's total profit for the year 2025 by 55.79 million yuan, with the final accounting treatment to be confirmed in the 2025 annual report [6].

证券代码：600351 证券简称：亚宝药业 公告编号：2025-033 亚宝药业集团股份有限公司 药品名称：SY-009胶囊 剂型：胶囊剂 规格：0.5mg、5mg 注册分类：化学药品第1类 申请人：亚宝药业集团股份有限公司、苏州亚宝药物研发有限公司 批件号：2018L02807、2018L02808、2024LP02207 关于研发项目终止临床试验并计提减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）对SY-009研发项目（以下简称"SY-009"）进行了 审慎评估，综合项目进展情况、继续开发的投入风险和未来的市场价值等多种因素，为合理配置公司研 发资源，聚焦研发管线中的优势项目，公司决定终止SY-009的临床研究开发工作，同时根据《企业会计 准则》等相关规定，基于会计谨慎性原则，将该项目研发资本化金额全额计提资产减值准备，现将有关 情况公告如下： 一、终止临床试验的药物基本信息 （一）本次计提资产减值准备的依据 依据《企业会计准则第8号-资产减值》及公司会计 ...